Work

Efecte de l'administració de l'rt-PA en condicions isquèmiques in vitro i in vivo: Cav-1 com a potencial biomarcador de volum d'infart

Year: 2019
Type: dissertation
Abstract: Recombinant tissue plasminogen activator (rt-PA) is currently the only FDA-approved drug for the treatment of acute ischaemic stroke. However, the application of this therapy is limited to <5-7% of patients due to the associated increased risk of haemorrhagic transformation (HT). Although it is known that HT is related to rt-PA-induced blood brain barrier (BBB) disruption, the underlying mechanisms are not well established. The obtained results show that long-term studies are needed to elucidate time-dependent molecular mechanisms associated to BBB breakdown, and to explore protective BBB therapies after ischaemic stroke and rt-PA treatment. On the other hand, it has been demonstrated that OGD induces significant alterations to loading control proteins for Western Blot analysis proposing Stain-Free technology as an alternative normalization method to traditional housekeeping proteins. Finally, serum Cav-1 levels could represent a potential biomarker predicting the ischaemic outcome before rt-PA administration
Language: Catalan
Field: Medicine
Open Access status: green
OpenAlex ID: W3037512531
Cites: 349
Cited by:
Related to: 10